47 min
Whipple’s Disease: When Should a Rheumatologist Take a Whiff of Whipple’s? Healio Rheuminations
-
- Medicine
This episode dives into the rare Whipple’s disease, focusing on the articular manifestations of this infectious masquerader and when a rheumatologist should consider it in the differential.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Intro :20 In this episode :28 Background on the organism 5:25 An important point when making the diagnosis 7:48 Who gets infected? 8:55 What is Whipple’s disease? 11:48 This disease is fatal 15:53 A look at the joints 16:28 What happens when you give these patients immunosuppression? 26:36 How to diagnose 28:38 Summary so far 31:00 Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com
Other organ manifestations of Whipple’s disease 32:08 Summary and take-home 44:36 Disclosure: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Bousbia S, et al. Emerg Infect Dis. 2010;16:258-63.
Chan RY, et al. Ophthalmology. 2001;108:2225-2231.
Dobbins 3rd WO, et al. Arthritis Rheum. 1987;30:102-105.
Durand DV, et al. Medicine (Baltimore). 1997;76:170-84.
Fenollar F, et al. BMC Infect Dis. 2011;11:171.
Feurle GE, et al. Eur J Clin Invest. 1979;9:385-389.
Geissdörfer W, et al. J Clin Microbiol. 2012;50:216-22.
Guérin A, et al. Elife. 2018;7:e32340.
Heffner DK. Lancet. 2007;370:738-9; author reply 739.
Keita AK, et al. PLoS Negl Trop Dis. 2011;5:e1403.
Lagier JC, et al. Medicine (Baltimore). 2010;89:337-345.
Lozupone C, et al. Am J Respir Crit Care Med. 2013;187:1110-7.
McAllister Jr. HA, Fenoglio Jr. JJ. Circulation. 1975;52:152-6.
O’Duffy JD, et al. Arthritis Rheum. 1999;42:812-817.
Puéchal X. Joint Bone Spine. 2016;83:631-635.
Puéchal X, et al. Arthritis Rheum. 2002;46:1130-1132.
Puéchal X, et al. Arthritis Rheum. 2007;56:1713-1718.
Raheja AA, et al. Clin Imaging. 2010;34:143-147.
Ramos JM, et al. J Med Case Rep. 2015;9:165.
Raoult D, et al. Emerg Infect Dis. 2010;16:776-82.
Schöniger-Hekele M, et al. Appl Environ Microbiol. 2007;73:2033-2035.
Stein A, et al. Am J Respir Crit Care Med. 2013;188:1036-7.
Additional resource:
Neurosigns.org’s video on oculomasticatory myorhythmia can be viewed at: https://www.youtube.com/watch?v=Zwb5bt749Jo
This episode dives into the rare Whipple’s disease, focusing on the articular manifestations of this infectious masquerader and when a rheumatologist should consider it in the differential.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Intro :20 In this episode :28 Background on the organism 5:25 An important point when making the diagnosis 7:48 Who gets infected? 8:55 What is Whipple’s disease? 11:48 This disease is fatal 15:53 A look at the joints 16:28 What happens when you give these patients immunosuppression? 26:36 How to diagnose 28:38 Summary so far 31:00 Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com
Other organ manifestations of Whipple’s disease 32:08 Summary and take-home 44:36 Disclosure: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Bousbia S, et al. Emerg Infect Dis. 2010;16:258-63.
Chan RY, et al. Ophthalmology. 2001;108:2225-2231.
Dobbins 3rd WO, et al. Arthritis Rheum. 1987;30:102-105.
Durand DV, et al. Medicine (Baltimore). 1997;76:170-84.
Fenollar F, et al. BMC Infect Dis. 2011;11:171.
Feurle GE, et al. Eur J Clin Invest. 1979;9:385-389.
Geissdörfer W, et al. J Clin Microbiol. 2012;50:216-22.
Guérin A, et al. Elife. 2018;7:e32340.
Heffner DK. Lancet. 2007;370:738-9; author reply 739.
Keita AK, et al. PLoS Negl Trop Dis. 2011;5:e1403.
Lagier JC, et al. Medicine (Baltimore). 2010;89:337-345.
Lozupone C, et al. Am J Respir Crit Care Med. 2013;187:1110-7.
McAllister Jr. HA, Fenoglio Jr. JJ. Circulation. 1975;52:152-6.
O’Duffy JD, et al. Arthritis Rheum. 1999;42:812-817.
Puéchal X. Joint Bone Spine. 2016;83:631-635.
Puéchal X, et al. Arthritis Rheum. 2002;46:1130-1132.
Puéchal X, et al. Arthritis Rheum. 2007;56:1713-1718.
Raheja AA, et al. Clin Imaging. 2010;34:143-147.
Ramos JM, et al. J Med Case Rep. 2015;9:165.
Raoult D, et al. Emerg Infect Dis. 2010;16:776-82.
Schöniger-Hekele M, et al. Appl Environ Microbiol. 2007;73:2033-2035.
Stein A, et al. Am J Respir Crit Care Med. 2013;188:1036-7.
Additional resource:
Neurosigns.org’s video on oculomasticatory myorhythmia can be viewed at: https://www.youtube.com/watch?v=Zwb5bt749Jo
47 min